STOCK TITAN
  1. Home
  2. Sec-filings
  3. GLMD
  4. [Form 3] Galmed Pharmaceuticals Ltd. Initial Statement of Beneficial Ownership

Galmed (GLMD) director discloses multiple stock option grants

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Galmed Pharmaceuticals Ltd. director Carol L. Brosgart filed an initial ownership report showing she holds several option grants to purchase Ordinary Shares. The options have exercise prices ranging from 1.4100 to 2080.8000 and expiration dates from 2027-04-25 through 2035-10-29. Footnotes state that portions of these options vest in stages between 2026 and 2028, subject to her continued service.

Positive

  • None.

Negative

  • None.
Insider Brosgart Carol L
Role Director
Type Security Shares Price Value
holding Options to Purchase Ordinary Shares -- -- --
holding Options to Purchase Ordinary Shares -- -- --
holding Options to Purchase Ordinary Shares -- -- --
holding Options to Purchase Ordinary Shares -- -- --
holding Options to Purchase Ordinary Shares -- -- --
holding Options to Purchase Ordinary Shares -- -- --
Holdings After Transaction: Options to Purchase Ordinary Shares — 111 shares (Direct)
Footnotes (1)
  1. These options vest on August 7, 2026, subject to the Reporting Person's continued service. These options vest in four equal installments on each of May 12, 2026, November 12, 2026, May 12, 2027 and November 12, 2027, subject to the Reporting Person's continued service. These options vest in accordance with the following vesting schedule: 1/3 shall vest on August 26, 2026 and the remaining portion shall vest in four equal installments on each of February 26, 2027, August 26, 2027, February 26, 2028 and August 26, 2028, subject to the Reporting Person's continued service.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding Insider Trading Forms →
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Brosgart Carol L
(Last)(First)(Middle)
C/O MEITAR LAW OFFICES
16 ABBA HILLEL SILVER RD.
(Street)
RAMAT GAN5250608
(City)(State)(Zip)
UNITED STATES
(Country)		2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026		3. Issuer Name and Ticker or Trading Symbol
Galmed Pharmaceuticals Ltd. [ GLMD ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Options to Purchase Ordinary Shares07/15/202107/15/2031Ordinary Shares111$558D
Options to Purchase Ordinary Shares07/10/201807/10/2028Ordinary Shares166$2,080.8D
Options to Purchase Ordinary Shares04/25/201704/25/2027Ordinary Shares166$876.6D
Options to Purchase Ordinary Shares08/07/202308/07/2033Ordinary Shares6,250(1)$12.6D
Options to Purchase Ordinary Shares11/12/202411/12/2034Ordinary Shares17,500(2)$2.88D
Options to Purchase Ordinary Shares10/29/202510/29/2035Ordinary Shares12,500(3)$1.41D
Explanation of Responses:
1. These options vest on August 7, 2026, subject to the Reporting Person's continued service.
2. These options vest in four equal installments on each of May 12, 2026, November 12, 2026, May 12, 2027 and November 12, 2027, subject to the Reporting Person's continued service.
3. These options vest in accordance with the following vesting schedule: 1/3 shall vest on August 26, 2026 and the remaining portion shall vest in four equal installments on each of February 26, 2027, August 26, 2027, February 26, 2028 and August 26, 2028, subject to the Reporting Person's continued service.
/s/ Carol L. Brosgart03/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What does Galmed Pharmaceuticals (GLMD) disclose in this Form 3?

Galmed Pharmaceuticals reports director Carol L. Brosgart’s option holdings. The filing lists multiple options to purchase Ordinary Shares with specific exercise prices, expiration dates, and vesting schedules that extend from 2026 through 2035, establishing her initial derivative ownership position.

Who is the reporting person in Galmed Pharmaceuticals (GLMD) Form 3?

The reporting person is Carol L. Brosgart, a director of Galmed. The Form 3 registers her status as an insider and details her beneficial ownership of options to purchase Ordinary Shares, including exercise prices, expiration timelines, and staged vesting conditions.

What stock options does Carol L. Brosgart hold in Galmed (GLMD)?

Brosgart holds several options to purchase Galmed Ordinary Shares. The grants have exercise prices such as 558.0000, 2080.8000, 876.6000, 12.6000, 2.8800, and 1.4100, with corresponding expiration dates between 2027 and 2035.

How do the Galmed (GLMD) options held by Carol L. Brosgart vest?

Several option grants vest over time subject to continued service. Footnotes describe schedules where options vest on specific dates in 2026, and then in installments on later dates in 2027 and 2028, conditional on Brosgart remaining in her role with the company.

Are there any buy or sell transactions in this Galmed (GLMD) Form 3?

No buy or sell trades are reported in this Form 3. The records are categorized as holdings, reflecting existing option positions rather than new purchases, sales, exercises, or gifts, and transaction direction fields are marked as unknown or neutral.

Why is Galmed Pharmaceuticals (GLMD) Form 3 important for investors?

The Form 3 establishes a baseline of insider derivative ownership. It shows which option grants a director currently holds, including strike prices, expirations, and vesting terms, giving investors a reference point for interpreting any future Form 4 or Form 5 transactions.